Radnostix Reports Q3 FY2026 Results With 15% Theranostics Sales Gain
Radnostix posts a 15% year-over-year rise in theranostics sales, agrees to sell fluorine assets, and files a key drug master file.
Radnostix, Inc., the Idaho Falls-based radioisotope manufacturer formerly known as International Isotopes Inc. and trading on the OTCQB under the ticker INIS, reported its financial results for the third quarter and first nine months of fiscal year 2026, highlighting a 15% year-over-year increase in theranostics sales as the standout performance metric.
Alongside the quarterly results, the company announced it has signed an agreement to sell its fluorine products and depleted uranium hexafluoride, or DUF6, assets to Nano Nuclear Energy. The divestiture signals a strategic narrowing of focus toward radioisotope-driven medical and research applications, though the precise financial terms of the transaction were not disclosed in the announcement.
Read more WPM Real Estate to Manage A&G's 14 Multifamily Communities →
Radnostix also disclosed that it has submitted a Type II Drug Master File, known as a DMF, for its Sodium Iodide I-131 active pharmaceutical ingredient. A Type II DMF submission to the U.S. Food and Drug Administration is a standard step manufacturers take to protect proprietary process information while enabling pharmaceutical partners to reference that data in their own drug applications, potentially broadening the commercial pathway for the company's I-131 product.
The combination of sales growth in theranostics — a field merging therapeutic and diagnostic nuclear medicine — along with the asset sale and regulatory filing positions Radnostix as a more concentrated radiopharmaceutical-focused enterprise heading into the final quarter of its fiscal year. The company's rebranding from International Isotopes Inc. reflects that strategic repositioning.
Continue reading at Earnings for the full financial tables and management commentary.